logo
[breadcrumb_custom]

Tag: Iterum Therapeutics plc (NASDAQ:ITRM)

Stock

ITRM’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect?

The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price loss of -24.37% this year. Over the last six months, there has been a weaker performance of 68.15%. The price of ITRM fallen by 4.93% during the last 30 days period. For the last 5-days stocks have improved 16.41%. The market performance of Iterum Therapeutics Plc’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point

Finance

Iterum Therapeutics Plc: Rising -34.00% from 52-Week Low, Can the Stock Stay Afloat?

Iterum Therapeutics Plc ‘s stock market performance has been somewhat predictable. The company’s stock reached a 1-year high price of $2.50 on 11/27/23, while the lowest value for the same period was recorded at $0.62 on 10/25/23. 52-week price history of ITRM Stock A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Iterum Therapeutics Plc’s current trading price is -34.00% away from its 52-week high, while its distance from the 52-week low is 165.27%. The stock’s price range during this period has spanned from $0.62 to $2.50. In the Healthcare sector, the

THMO
Stock

The ITRM Stock Puzzle: Unraveling Iterum Therapeutics Plc’s Fluctuating Performance

Iterum Therapeutics Plc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $2.50 on 11/27/23 and a low of $0.62 for the same time frame on 10/25/23. 52-week price history of ITRM Stock A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Iterum Therapeutics Plc’s current trading price is -29.40% away from its 52-week high, while its distance from the 52-week low is 183.76%. The stock’s price range during this period has spanned from $0.62 to $2.50. In the Healthcare sector, the Iterum Therapeutics Plc’s